The results denoted that the expression of SEC61A1 was significantly increased in AML patients, compared to controls (GSE7186, P = 0.0435; GSE13159, P < 0.0001) (Figure 1a and b). The gene discussed is SEC61A1; the disease is acute myeloid leukemia.